Clinical trials: Hematopoietic and Lymphatic System Neoplasm
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials
This clinical trial evaluates a clinical trial navigation intervention to help increase participation and diversity in cancer clinical trials.
- Trial name
- GUIDE (NCT06484595)
- Testing
- Best Practice, Patient Navigation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors.
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT04593277
- Testing
- Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 549 people
- Sponsor
- Fred Hutchinson Cancer Center
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma
- Trial name
- NCT00084695
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Multiple Myeloma, Auto Stem Cell Transplant
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant…
- Trial name
- (Mel/MelVel) (NCT01241708)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Hackensack Meridian Health
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Lung Non-Small Cell Carcinoma
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment.
- Trial name
- NCT05106374
- Testing
- Biospecimen Collection, Cognitive Assessment, Physical Performance Testing
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
Zevalin-beam for Aggressive Lymphoma
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will…
- Trial name
- NCT00491491
- Testing
- ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation
Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
HLA-mismatched unrelated donor (MMUD) and HLA-haploidentical donor (Haplo Donor) hematopoietic stem cell transplantation (HSCT) is associated with increased graft-versus-host-disease (GVHD) and impaired survival.
- Trial name
- NCT02799888
- Testing
- Maraviroc, Cyclosporine (in HLA-Unrelated Donor Transplantation), Tacrolimus (in HLA-Mismatched Related Donor Transplantation)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Lymphoma, Non-Hodgkin Lymphoma
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT06915246
- Testing
- VI-0609, BiCNU
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- VIVUS LLC
Breast Carcinoma, Esophageal Carcinoma
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself.
- Conditions
- Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT00991094
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies, Myelogenous Leukemia
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
- Conditions
- Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00144703
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed/Refractory Diffuse Large B Cell Lymphoma
Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aims to evaluate the efficacy and safety of tafasitamab combined with lenalidomide plus standard immunochemotherapy, followed by sequential autologous stem cell transplantation (ASCT), in patients with…
- Trial name
- NCT07621406
- Testing
- Treatment with the Tafa+Len+ standard immunotherapy regimen (e.g., R-ICE, R-DHAP, R-GDP, etc.)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematopoietic and Lymphoid System Neoplasm, Lymphedema
Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study
This clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema).
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Lymphedema, Malignant Solid Neoplasm
- Trial name
- NCT06305884
- Testing
- Bioelectric Impedance Analysis, Exercise, Photoplethysmography
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Plasma Cell Myeloma
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation.
- Trial name
- NCT03417284
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Lymphoma
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Primary Objective: A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients receiving a non-myeloablative allogeneic SCT from a matched sibling donor, with fludarabine and low-dose…
- Conditions
- Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Trial name
- NCT00304720
- Testing
- Tacrolimus and MMF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Colorado Blood Cancer Institute
Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific…
- Conditions
- Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
- Trial name
- NCT05544968
- Testing
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical College of Wisconsin
Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
- Trial name
- NCT06600659
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Fluoroquinolone Resistance Prevalence Study
This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple…
- Trial name
- FRE (NCT05824689)
- Where
- 2 sites in United States
- Volunteers
- 124 people
- Sponsor
- Hackensack Meridian Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.